Ratings for Staar Surgical (NASDAQ:STAA) have been given by four analysts over the past three months and show a mix of bullish and bearish perspectives.
The following table summarizes their recent ratings, offering a look at the changing sentiments over the past 30 days and comparing them to the previous months.
| Bullish | Somewhat bullish | Indifferent | Somewhat bearish | Bearish | |
|---|---|---|---|---|---|
| Total reviews | 1 | 0 | 3 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1 million ago | 0 | 0 | 1 | 0 | 0 |
| 2M ago | 0 | 0 | 2 | 0 | 0 |
| 3M ago | 0 | 0 | 0 | 0 | 0 |
Insights from analysts’ 12-month price targets are revealed, with an average price target of $26.25, a high estimate of $30.75, and a low estimate of $21.50. With an 8.5% decline, the current average is now lower than the previous average price target of $28.69.
Analyst Ratings Analysis: A Detailed Survey
A clear picture of Staar Surgical’s perception among financial experts is outlined with an in-depth analysis of recent analyst actions. The overview below provides an overview of the top analysts, their recent evaluations and adjustments to ratings and price targets.
Key insights:
Navigating these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Staar Surgical’s market position. Stay informed and make data-driven decisions with our assessment table.
Stay up to date with Staar Surgical analyst ratings.
If you’re interested in following the news and performance of small cap stocks, you can start here.
Discovering Cataract Surgical: a closer look
Staar Surgical: financial performance dissected
Market Capitalization Perspectives: The company’s market capitalization is below the industry average, indicating a relatively smaller size compared to peers. This positioning can be influenced by factors such as perceived growth potential or operational scale.
Sales growth: Staar Surgical’s remarkable performance in 3M is clearly visible. As of September 30, 2025, the company achieved impressive revenue growth of 6.93%. This means a significant increase in the company’s turnover. Compared to its peers, the company achieved a growth rate that was higher than the average for healthcare industry peers.
Net margin: Staar Surgical’s net margin exceeds industry benchmarks and extends beyond 9.38%. This means efficient cost management and strong financial health.
Return on Equity (ROE): Staar Surgical’s ROE lags behind industry averages, highlighting challenges in maximizing return on equity. With an ROE of 2.57%, the company may encounter obstacles in achieving optimal financial performance.
Return on Assets (ROA): Staar Surgical’s financial strength is reflected in its exceptional ROA, which is higher than industry averages. With a remarkable ROA of 1.99%, the company demonstrates efficient use of assets and strong financial health.
Debt management: Staar Surgical’s debt-to-equity ratio is below industry standards, indicating a healthy financial structure with a ratio of 0.11.
How are analyst ratings determined?
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts can attend company conference calls and meetings, research companies’ financial statements, and communicate with insiders to publish “analyst ratings” for stocks. Analysts typically rate each stock once a quarter.
Analysts can supplement their ratings with forecasts for metrics such as growth estimates, earnings and revenue, giving investors a more comprehensive view. However, investors should keep in mind that analysts, like any human being, may have subjective perspectives that influence their predictions.
This article was generated by Benzinga’s automated content engine and reviewed by an editor.
#Rating #Staar #Surgical #Insights #Financial #Analysts #Staar #Surgical #NASDAQSTAA